
Brian Alexander: Honored to participate in the NCI’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice
Brian Alexander, CEO of Foundation Medicine, shared a post by Foundation Medicine on LinkedIn, adding;
“Honored to participate in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.”
Qouting Foundation Medicine‘s post:
“Proud to announce our participation in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer. This initiative is the largest of its kind to test the effectiveness of biomarker-targeted cancer treatment combinations to seek improvement in patient outcomes. Foundation Medicine is one of the largest contributors of potential participants to ComboMATCH, in connection with which Foundation Medicine testing results will help determine trial eligibility for patients. ”
Read more at the link here.
For the video attached to the post click here.
Source: Brian Alexander/LinkedIn and Foundation Medicine/LinkedIn
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows